NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
anti-CTLA-4/LAG-3 bispecific antibody XmAb22841
An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4/LAG-3 bispecific antibody XmAb22841 targets and binds to both CTLA-4 and LAG-3 expressed on T cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-CTLA-4/anti-LAG-3 bispecific monoclonal antibody XmAb22841
CTLA-4xLAG-3 bispecific antibody XmAb22841
Code name:XmAb 22841
XmAb22841
XmAb-22841